Hemostemix Inc's stock is experiencing a significant downturn, raising concerns among investors.
Hemostemix Inc (HEM.V) has seen its stock price drop by 7.69% in today's trading session, closing at CA$0.06. This decline comes amidst a lack of positive news and investor uncertainty in the small-cap biotech sector.
Advertisement
Hemostemix Inc
HEM.V
HEM.V
Hemostemix Inc
WealthAwesomeAdvertisement
Market cap
$13.32M
52W high
$0.14
52W low
$0.04
1W change
+15.38%
Beta
0.61
Analyst Price Targets
Based on analyst covering HEM
Wall Street analysts forecast HEM stock price to rise 1180.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.96
+1180.0% Upside
Current Price
C$0.07
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HEM's historical volatility
30-Day Vol
140.1%
Annualized
90-Day Vol
116.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.08 | C$0.05 – C$0.13 |
| 60 trading days | C$0.08 | C$0.04 – C$0.17 |
| 90 trading days | C$0.09 | C$0.04 – C$0.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should be cautious as Hemostemix faces challenges in maintaining its stock value amid ongoing market volatility and limited news flow.
Stock down 7.69% today
Hemostemix's market cap now stands at approximately CA$13.32 million, reflecting investor concerns over its financial health.
Bull case
If Hemostemix can successfully advance its clinical trials and secure additional funding, there could be a chance for its stock price to recover in the long run.
Bear case
On the flip side, ongoing weakness in the stock price might signal deeper issues within the company, especially if it struggles to build investor confidence or meet its clinical goals.
Market Reaction
Advertisement
The market reacted negatively to Hemostemix's recent actions, including private placements that raised funds at lower share prices. Investors are likely worried about share dilution and whether the company can effectively use the capital it raised.
Investor Sentiment
Investor sentiment seems to be shifting as the stock continues to decline. With no significant news to boost confidence, many are questioning the viability of Hemostemix's business model and its long-term prospects in the competitive biotech landscape.
Looking Ahead
As Hemostemix Inc navigates this downturn, investors will be closely watching for any announcements about its clinical trials and partnerships. The company's ability to regain momentum will depend heavily on its operational progress and strategic decisions moving forward.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
